Shingles Vaccine Showed Protection in Multiple Sclerosis
Adults with multiple sclerosis saw reduced risk of shingles after vaccination in a new study.
Updated on Sept. 25, 2026 in Stroke
Live Poll
Does new research on vaccine effectiveness increase your trust in the recombinant zoster vaccine?
Researchers from Harvard Medical School found that the recombinant zoster vaccine was effective at preventing shingles in patients living with multiple sclerosis. The study analyzed data from both Medicare and commercially insured cohorts to determine the vaccine's protective impact.
Why it matters
This research provides clinical evidence for the effectiveness of the recombinant zoster vaccine in individuals with multiple sclerosis, a population often at higher risk for infections. Understanding how well the vaccine works in this group helps clarify prevention strategies for those managing complex autoimmune conditions.
A cohort study utilizing Cox models with inverse probability of treatment weighting evaluated the vaccine's effectiveness in patients aged 50 and older. The analysis included 8,705 vaccinated Medicare patients and 6,025 commercially insured vaccinated patients compared to their respective unvaccinated controls.
The players
Harvard Medical School
A prominent research and medical education institution that leads studies on public health and clinical outcomes.
GlaxoSmithKline
A global pharmaceutical company that produces vaccines, including the recombinant zoster vaccine.
The details
The study examined the recombinant zoster vaccine, which is administered in two doses at least 28 days apart to stimulate an immune response against the varicella-zoster virus. Researchers used Cox models to account for potential confounding factors, ensuring that the measured reduction in shingles incidence was associated with the immunization. The findings suggest the two-dose regimen maintains efficacy even within a population managing multiple sclerosis.
Timeline
January 2018 to September 2023: The period of data collection for the study.
September 25, 2026: Publication date of the research findings.
Health Landscape
This study expands on the established efficacy of the recombinant zoster vaccine clinical program by demonstrating its performance specifically within the vulnerable multiple sclerosis patient population. These findings clarify how preventive measures can be successfully integrated into the management of autoimmune conditions.
Patients managing multiple sclerosis should discuss the benefits and timing of the recombinant zoster vaccine with their primary care physician or neurologist. While this data suggests strong protection, your doctor can best evaluate how vaccination fits into your overall treatment plan and medication schedule.
The takeaway
The recombinant zoster vaccine demonstrates significant effectiveness in preventing shingles among individuals with multiple sclerosis. If you are living with this condition, ask your physician about the current vaccination recommendations and whether this preventive measure is appropriate for you.
Further reading
For more information on managing neurological health, visit the Stroke section.
More information
Review the complete journal article and citation for further technical analysis.
Source note: This article includes information reported by InsuranceNewsNet.
Live Poll
Does new research on vaccine effectiveness increase your trust in the recombinant zoster vaccine?
